Celestine Azubuike Afiukwa

Celestine Azubuike Afiukwa

Auto-generated profile, based on publicly available information

Celestine Azubuike Afiukwa

Ebonyi State University

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2020 in Endocrine, Metabolic & Immune Disorders - Drug Targets
Verified
Journal Article
Closed access
PDF file
GEGODWILL ENGWA
GODWILL ENGWA
FNFriday Nwalo Nweke
Friday Nwalo Nweke
GKGilbert Nfor Karngong
Gilbert Nfor Karngong
CACelestine Azubuike Afiukwa
Celestine Azubuike Afiukwa
KNKingsley Ekene Nwagu
Kingsley Ekene Nwagu
Type 2 diabetes (T2D) is a chronic non-communicable disease that is of major health concern with a steadily rising prevalence across the globe. It is a metabolic disorder characterized by high blood glucose level either as a result of impaired insulin secretion and/or insulin action usually termed insulin resistance. This disease is influenced by lifestyle/feeding habit changes and genetic factors that cause physiological changes in glucose and lipid metabolism. As such, antidiabetic treatments have targeted specific enzymes, receptors, transport proteins, hormones, transcription factors, etc. that are related to glucose metabolism, fat metabolism, insulin secretion and insulin signalization. Genetic variations due to mutations in certain target genes have been shown to influence the pathogenesis of T2D but also these polymorphisms have been observed to alter the therapeutic efficacy of drugs as well as their safety. Pharmacogenetic studies have been able to identify specific genetic variants of target genes that affect the metabolism, therapeutic response and adverse effects of antidiabetic drugs with the aim to translate the research findings to clinical practice. However, pharmacogenetic studies have not fully been able to identify distinct genetic markers that can serve as biomarkers for genetic screening, thus, limiting personalised medicine. As we advocate personalised medicine for the management of T2D in the future, pharmacogenetic studies should lay emphasis on addressing challenges of genetic screening and its translation to personalised therapy.

3 March 2024 in Cogent Food & Agriculture
Verified
Journal Article
Open access
DMDesalegn Abebe Mekonen
Desalegn Abebe Mekonen
AAAdane Abraham
Adane Abraham
HOHappiness Oselebe
Happiness Oselebe
CACelestine Afiukwa
Celestine Afiukwa
TATiegist Dejene Abebe
Tiegist Dejene Abebe
AAAderajew Adgo
Aderajew Adgo

4 November 2021
Verified
Book Chapter
Closed access
PDF file
CACelestine Azubuike Afiukwa
Celestine Azubuike Afiukwa
DIDavid Okeh Igwe
David Okeh Igwe
BUBenjamin Ewa Ubi
Benjamin Ewa Ubi